Celldex Therapeutics (CLDX) Expected to Announce Quarterly Earnings on Monday

Celldex Therapeutics (NASDAQ:CLDX) is projected to issue its quarterly earnings data before the market opens on Monday, February 24th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $1.31 million for the quarter.

Celldex Therapeutics Trading Down 1.6 %

Celldex Therapeutics stock opened at $22.70 on Monday. The firm has a market capitalization of $1.51 billion, a P/E ratio of -8.83 and a beta of 1.60. The stock has a fifty day moving average price of $24.70 and a 200 day moving average price of $29.73. Celldex Therapeutics has a 52 week low of $20.91 and a 52 week high of $53.18.

Analysts Set New Price Targets

CLDX has been the subject of several analyst reports. UBS Group initiated coverage on Celldex Therapeutics in a research note on Thursday. They issued a “buy” rating and a $44.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.22.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.